20 completed, 10 unknown, 3 recruiting, 2 suspended. 12 Phase 4, 9 Phase 3, 5 Not applicable, 4 Phase 1, 4 Phase 2.
Follow Indapamide: new trials by email Literature Review of Indapamide trials Research Report on Indapamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) Indapamide - Multiple Sclerosis | Phase 2 | Not yet recruiting | Eva M.M. Strijbis | 75 | 2026-09-01 | 2026-08-14 |
| Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism Indapamide 1.5 MG SR, Placebo - Hypoparathyroidism Post-surgical | Phase 4 | Recruiting | Lars Rejnmark | 24 | 2025-08-01 | 2025-08-11 |
| Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention Indapamide 2.5 MG, Hydrochlorothiazide 50Mg, Chlorthalidone 25mg - Kidney Stone | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 99 | 2024-10-01 | 2026-05-06 |
| Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH) Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg, Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg, Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg - Arterial Hypertension, HTN | Completed | Servier Russia | 396 | 2024-05-01 | 2025-06-11 | |
| Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine), Usual Care Antihypertensive Regimen - Apparent Resistant Hypertension, Hypertension | Not applicable | Recruiting | Instituto Dante Pazzanese de Cardiologia | 142 | 2023-07-15 | 2025-12-02 |
| Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet - Bioequivalence | Phase 1 | Unknown | Pharmtechnology LLC | 50 | 2023-06-24 | 2023-07-11 |
| A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy Fimasartan + Indapamide, Fimasartan + Indapamide placebo - Essential Hypertension | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 248 | 2022-11-09 | 2024-12-20 |
| Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India Amlodipine + Perindopril, Perindopril + Indapamide, Amlodipine + Indapamide - Primary Hypertension | Phase 4 | Completed | Centre for Chronic Disease Control, India | 1981 | 2022-08-30 | 2024-10-08 |
| Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg, Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) - Hypertension, Hypertension,Essential | Phase 3 | Unknown | Brainfarma Industria Química e Farmacêutica S/A | 400 | 2022-08-01 | 2022-03-21 |
| Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians Indapamide 1.5 MG SR - Pharmacogenomics | Phase 4 | Unknown | Ain Shams University | 38 | 2022-03-15 | 2022-03-24 |
| Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) Indapamide, Amlodipine, Olmesartan - Hypertension | Phase 2 | Completed | Alnylam Pharmaceuticals | 663 | 2021-11-05 | 2025-11-03 |
| Hydroxychloroquine and Indapamide in SPMS Hydroxychloroquine Pill, Indapamide Pill - Multiple Sclerosis, Secondary Progressive | Phase 2 | Unknown | University of Calgary | 35 | 2021-10-01 | 2022-05-18 |
| A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy Volunteers BR1015-1, BR1015-2, BR1015-1 + BR1015-2 - Hypertension | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 31 | 2021-08-16 | 2021-11-22 |
| Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 1385 | 2021-07-09 | 2025-06-03 |
| Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 755 | 2021-06-14 | 2025-06-03 |
| Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets, TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets - Bioequivalence, Healthy Subjects | Phase 1 | Completed | Darnitsa Pharmaceutical Company | 52 | 2021-05-30 | 2022-07-22 |
| Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets, Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets - Bioequivalence, Healthy Subjects | Phase 1 | Completed | Darnitsa Pharmaceutical Company | 42 | 2021-05-19 | 2022-07-19 |
| Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension AGSAVI, AGLS - Hypertension | Phase 3 | Unknown | Ahn-Gook Pharmaceuticals Co.,Ltd | 306 | 2021-02-01 | 2020-12-29 |
| The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure Spironolactone, Indapamide - Hypertension | Phase 4 | Unknown | Shanghai Jiao Tong University School of Medicine | 200 | 2020-09-23 | 2021-12-08 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
Showing 20 of 38. Sign in to see all of them.
Hypertension (26) · Cerebral Hemorrhage (3) · Essential Hypertension (3) · Cerebral Small Vessel Diseases (2) · Dementia, Vascular (2) · Multiple Sclerosis, Chronic Progressive (2) · Stroke (2) · COVID-19 (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hemorrhagic Stroke (1) · Hypercalciuria (1)
Boryung Pharmaceutical Co., Ltd (3) · The George Institute (3) · Darnitsa Pharmaceutical Company (2) · George Medicines PTY Limited (2) · Servier Russia (2) · University of Roma La Sapienza (2) · Ahn-Gook Pharmaceuticals Co.,Ltd (1) · Ain Shams University (1) · Alnylam Pharmaceuticals (1) · Brainfarma Industria Química e Farmacêutica S/A (1) · Centre for Chronic Disease Control, India (1) · EMS (1) · Eva M.M. Strijbis (1) · Hospices Civils de Lyon (1) · Hospital Authority, Hong Kong (1)
Australia (5) · China (5) · United Kingdom (4) · United States (4) · Brazil (3) · Poland (3) · Russia (3) · South Korea (3) · Sri Lanka (3) · Canada (2) · Italy (2) · Jordan (2) · Netherlands (2) · Nigeria (2) · Czechia (1)
Anthony Rodgers, Professor (2) · Carlo Gaudio, MD (2) · Adam P Bress, PharmD, MS (1) · Alexandra Konradi (1) · An-Hye Kim, M.D. Ph.D (1) · Craig Anderson (1) · Craig Anderson, Prof (1) · Daniel G Fuster, M.D. (1) · Dorairaj Prabhakaran, DM Cardiology (1) · Dragos Vinereanu, Professor, MD, PhD (1) · Irina Rodyukova (1) · John William McEvoy, MBBCh MHS (1) · Konstantinos Tsioufis, Professor (1)
PMID 19407805, PMID 21617110, PMID 21884956, PMID 24739801, PMID 26399404, PMID 26876066, PMID 27522394, PMID 31262348, PMID 33891615, PMID 34022170, PMID 34503866, PMID 34994269, PMID 39217570, PMID 39426836, PMID 40434761, PMID 40715816, PMID 41180852, PMID 42019018, PMID 42163997